Ticker

hVIVO plc (OPORF) Q4 2025 Earnings Call Transcript

hVIVO PLC (AIM:HVO), the human challenge trial specialist, reported a sharp fall in revenue and profitability for 2025, but Cavendish argued on Wednesday that the numbers mask a more encouraging underlying story and that the company is better positioned heading into 2026 than the headline figures suggest. The broker, which maintains a 'buy' rating and 16.5p target price against a current share price of 8.7p, kept…

hVIVO PLC (AIM:HVO), the AIM-listed human challenge trial specialist, expects high single-digit revenue growth in 2026, weighted to the second half, as it moves past a year of deliberate restructuring. The London-based clinical development company posted revenue of £46.8 million for the year ended 31 December, down from £62.7 million the prior year.

Cavendish has maintained its 'buy' recommendation and 16.5p target price on hVIVO PLC (AIM:HVO) following the clinical development specialist's announcement of a new influenza human challenge trial contract with Traws Pharma. The broker described the deal as consistent with the company's strong offering in the antiviral market.

hVIVO PLC (AIM:HVO) shares rose 11% to 8.18p after the clinical development specialist announced a new influenza human challenge trial contract and unveiled a unified brand identity on the same day, marking what the company says is the completion of its transformation into a fully integrated drug development partner. The trial agreement with Traws Pharma will see hVIVO test tivoxavir marboxil, an investigational…